Additional Value for Urinary 5-Hydroxyindoleacetic Acid as Prognostic Marker in Neuroendocrine Tumors? Abstract #1517

Introduction: 5-Hydroxyindoleacetic Acid (5-HIAA) is of value for diagnosis of NETs and correlates with severity of carcinoid syndrome. However its value for determining prognosis is uncertain, particularly in combination with other biomarkers
Aim(s): to determine prognostic value of 5-HIAA for overall survival (OS) in patients with a midgut NET or unknown primary and to compare prognostic value with patient characteristics, grade, stage, chromogranin A (Cga) and neuron-specific enolase (NSE)
Materials and methods: data were collected from all patients with a midgut NET or a NET from unknown primary with available 5-HIAA in 24 hour urine samples. Results were stratified for 5-HIAA and CgA: <2x upper limit of normal (ULN), 2-10x ULN or >10x ULN. For NSE this was reference range or >1xULN. OS was compared using a Kaplan Meijer with log rank test and hazard ratios were calculated using Cox-regression for univariate and multivariate analyses
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wouter Zandee
Keywords: prognosis 5-HIAA

To read results and conclusion, please login ...

Further abstracts you may be interested in

#34 Plasma Chromogranin A(CgA) and Urinary 5 Hydroxy-indoleacetic acid(5-HIAA) use in monitoring somatostatin analogue(SSA) therapy at Newcastle NHS Foundation Trust
Introduction: Two main biochemical markers, plasma chromogranin A (CgA) and urinary 5 hydroxy-indoleacetic acid (5-HIAA) are used to aid staging and monitoring of patients with neuroendocrine (NET) tumors. Somatostatin analogues (SSA) such as octreotide and lanreotide have been used to alleviate symptoms and disease progression in NET patients. This study evaluates the use of CgA and 5HIAA in monitoring NET patients on SSA therapy at Newcastle NHS Foundation Trust.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Andy James
Authors: Teo L, Hearn K, Bernstone G, Wright R, ...
#1543 Is True Non-Secretion of Chromogranin A an Unfavorable Prognostic Factor in Patients with ENETs TNM Stage IV Gastroenteropancreatic Neuroendocrine Tumors?
Introduction: Chromogranin A (CgA) is the best available serum marker for the work-up of gastroenteropancreatic NETs (GEP-NETs) and correlates with tumor volume & biological activity. During diagnosis & follow-up we found patients with elevated CgA levels and patients without elevated CgA levels (=‘true non-secretors’). We postulated that lack of secretion is a sign of dedifferentiation with a poorer prognosis.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: drs. Kimberly Kamp
Keywords: GEP-NET, CgA, prognosis
#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review
Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Marion Feuilly
Authors: Haig J, Kohli M, Pastor L, Feuilly M, ...
#1142 GastroEnteroPancreatic and Thoracic Neuroendocrine Tumors and the Ectopic Adrenocorticotropin Syndrome
Introduction: Ectopic Adrenocorticotropin (ACTH) Syndrome (EAS) is associated with a variety of malignancies, predominantly of neuroendocrine origin. Several series report on the relative contribution of EAS in the spectrum of Cushing’s syndrome. However, information on the incidence/prevalence and prognosis of EAS in the setting of patients diagnosed with Thoracic or GEP-NETs is virtually absent.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: drs. Kimberly Kamp
#1935 Prevalence of Pancreatic Neuroendocrine Neoplasms with Serotonin Secretion
Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are rare neoplasms and represent 1-2% of all pancreatic neoplasms. These tumors can secrete a variety of hormonally active substances producing distinct clinical symptoms, or can be clinically non-functioning. Pancreatic NENs that secrete serotonin are extremely rare, but their prevalence has not been explored adequately.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, MSc, PhD Nikolaos Tsoukalas
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.